Preclinical Study Published in Molecular Therapy Demonstrates Why a Laterally Spreading Capsid Is Essential for Safe and Effective Retinal Gene Therapy in XLRS

AAV.SPR capsid delivers RS1 to foveal photoreceptors from a safe, peripheral injection site, overcoming problems experienced with conventional AAV capsids Atsena’s lead AAV.SPR program, ATSN-201, … The post Preclinical Study Published in Molecular Therapy Demonstrates Why a Laterally Spreading Capsid Is Essential for Safe and Effective Retinal Gene Therapy in XLRS appeared first on Atsena Therapeutics .